NCT Number: NCT01650948
Genetic Load and Phenotype in Aggressive AMD
Patients with AMD will provide cheek cell samples to determine if their is a correlation between genotype (DNA markers) and phenotype (the type of AMD the patient has).
Looking for future studies?
Notify MeKey information
Conditions
Age range
50 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
Pacific Eye Associates, San Francisco, California, United States
About this study
This study seeks to test individuals who have already progressed to various forms of AMD to evaluate correlations between genetic markers and particular features of AMD including geographic atrophy and pigment epithelial detachments. We hypothesize that patients with more aggressive forms of AMD will have a higher genetic burden contributed by markers in ARMS 2, Complement Factor H (CFH), Complement component 3 (C3), Complement component 2 (C2) , Factor B (FB), or other genetic polymorphisms associated with CNV.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Subject is male or female 50 years of age and older
- Subject provides a signed and dated informed consent
- Subject agrees to provide two buccal swabs in accordance with this protocol
- Diagnosis of CNV secondary to AMD in at least one eye
Exclusion criteria
- Previous sample donation under this protocol
- Presence of retinal disease involving the photoreceptors and/or outer retinal layers other than AMD loss such as high myopia, retinal dystrophies, central serous retinopathy, vein occlusion, diabetic retinopathy and uveitis or similar outer retinal diseases which have been present prior to the age of 50.
- Opacities of the ocular media, limitations of pupillary dilation or other problems sufficient to preclude adequate imaging of the posterior segment.
Treatment and study plan
Primary outcomes
-
The identification of individual genetic markers or a quantitative measure of total genetic burden found to be significantly associated (p value <0.05) with group classification (CNV only versus CNV with GA and/or RPED).
Time frame: 1 day
Sponsors and collaborators
Lead sponsor
Sequenom, Inc.
Industry
Registry information
Official study title
Evaluation of Genetic Variants in Patients Under Treatment for Choroidal Neovascular (CNV) Age-related Macular Degeneration (AMD), Receiving Intravitreal antiVEGF Injections to Evaluate the Association Between Genetic Load and Phenotypes Associated With More Aggressive Forms of Disease.
Acronym: RPED Genetics
Important dates
- Study start
- 2012
- Primary completion
- 2013
- Study completion
- 2013
- First posted
- Jul 26, 2012
- Registry last updated
- Jan 20, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Natural History of Geographic Atrophy Associated With Age-Related Macular Degeneration
NCT02941263
Age-Related Macular Degeneration, Eye Diseases
Bethesda, Maryland, United States
View Trial DetailsStudy of Dark Adaptation in Age-Related Macular Degeneration
NCT01352975
Age-Related Macular Degeneration, Eye Diseases
Bethesda, Maryland, United States
View Trial DetailsA 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT06190093
Age-Related Macular Degeneration, Eye Diseases
Arcadia, California, United States
View Trial DetailsEvaluation of Kamuvudine-8 in Subjects With Geographic Atrophy
NCT06164587
Age-Related Macular Degeneration, Eye Diseases
Loma Linda, California, United States
View Trial Details